FDA Issues Draft Guidance on Responding to Form 483 Observations
In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection…
Read the full articleYou might also wanna read
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
On June 2, the US Food and Drug Administration (FDA) released a new draft guidance called “Leveraging Prior Knowledge in the Development of
jdsupra.com·28d ago
FDA PCAC Hearing July 2026: What's at Stake for Compounded Peptide Access
Follow the July 23-24, 2026 FDA hearing on peptide compounding, get hearing updates, and tell the FDA your position before the comment deadl
pepmed.org·9d ago
Part II: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting.
Statement on FDA’s delay of GRAS amendment proposal
Statement on FDA’s delay of GRAS amendment proposal Iris Myers July 9, 2026 WASHINGTON – The Food and Drug Administration’s plan to amend th
Part I: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting.
FDA warns six importers in five states for food safety failures tied to tea, produce and sauces
As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some lette
Comments
Sign in to join the conversation.
No comments yet. Be the first.